Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 27 Neoplasms 20 Cancer Pain 10 Colonic Neoplasms 7 Breakthrough Pain 7 Agnosia 7 Breast Neoplasms 5 Rectal Neoplasms 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Head and Neck Neoplasms 4 Chronic Pain 4 Urinary Bladder Neoplasms 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Pain, Postoperative 3 Lymphoma, Follicular 3 Breakthrough Cancer Pain 3 Waldenstrom Macroglobulinemia 2 Uterine Cervical Neoplasms 2 Thrombocythemia, Essential 2 Sezary Syndrome 2 Primary Myelofibrosis 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Polycythemia Vera 2 Pleural Effusion, Malignant 2 Pdgfra-Associated Chronic Eosinophilic Leukemia 2 Myeloproliferative Disorders 2 Mycosis Fungoides 2

Interventions

Denosumab 2 radium Ra 223 dichloride 1 Radiotherapy 1 Radiation 1 QL1206 1 Magnetic Resonance Spectroscopy 1 Hydroxychloroquine 1 Fentanyl 1 Exercise 1 Docetaxel 1 Continuous Glucose Monitoring 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Metastases × Fentanyl × Clear all

NCT03071744 2019-12-09

Lazanda in Cancer Patients Receiving Palliative Radiation

University of California, San Diego

Phase 2 Terminated

6 enrolled 10 charts

Bone Metastases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡